A review article discussing predictive factors in RA, suggested that lower serum levels of interferon-γ and of BAFF, presence of the Fcγ receptor III genotype, the C/G-174 IL-6 polymorphism, or rheumatoid factor positivity, were associated with clinical response after rituximab therapy [57]. The gene discussed is IL6; the disease is rheumatoid arthritis.